Reperfusion Injury. Putting the Genie Back in the Bottle?

Journal of the American College of Cardiology

Volumn 55, Issue 12, 2010, Pages 1206-1208

  Reichek, Nathaniel ^a   Parcham Azad, Kambiz ^a  

^a ST FRANCIS HOSPITAL   (United States)

Author keywords

cardiac MRI; cyclosporine; myocardial infarction; reperfusion injury

Indexed keywords

CYCLOSPORIN; REACTIVE OXYGEN METABOLITE;

DRUG BINDING; DRUG INHIBITION; EDITORIAL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION INJURY; SINGLE DRUG DOSE; ST SEGMENT ELEVATION;

CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MYOCARDIAL REPERFUSION INJURY; TREATMENT OUTCOME;

EID: 77949334802     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.10.048     Document Type: Editorial

References (48)

1. Wikipedia. Genie. http://en.wikipedia.org/wiki/Genie Accessed October 20, 2009
2. Mewton N., Croisille P., Gahide G., et al. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol 55 (2010) 1200-1205
3. Jennings R.B., Ganote C.E., and Reimer K.A. Ischemic tissue injury. Am J Pathol 81 (1975) 179-198
4. Mathur V.S., Guinn G.A., and Burris III W.H. Maximal revascularization(reperfusion) in intact conscious dogs after 2 to 5 hours of coronary occlusion. Am J Cardiol 36 (1975) 252-261
5. Rentrop P., De Vivie E.R., Karsch K.R., and Kreuzer H. Acute coronary occlusion with impending infarction as an angiographic complication relieved by a guide-wire recanalization. Clin Cardiol 1 (1978) 101-106
6. Rentrop P., Blanke H., Karsch K.R., Kaiser H., Kostering H., and Leitz K. Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation 63 (1981) 307-317
7. Collen D., Topol E.J., Tiefenbrunn A.J., et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 70 (1984) 1012-1017
8. Braunwald E., and Kloner R.A. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 66 (1982) 1146-1149
9. Krug A., Du Mesnil de Rochemont R., and Korb G. Blood supply of the myocardium after temporary coronary occlusion. Circ Res 19 (1966) 57-62
10. Ito H. No-reflow phenomenon and prognosis in patients with acute myocardial infarction. Nat Clin Pract Cardiovasc Med 3 (2006) 499-506
11. Manning A.S., and Hearse D.J. Reperfusion induced arrhythmias: mechanisms and prevention. J Mol Cell Cardiol 16 (1984) 497-518
12. Bolli R., and Marbán E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 79 (1999) 609-634
13. Xu Y., Huo Y., Toufektsian M.C., et al. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 290 (2006) H692
14. Yellon D.M., and Hausenloy D.J. Myocardial reperfusion injury. N Engl J Med 357 (2007) 1121-1135
15. Bialik S., Cryns V.L., Drincic A., et al. The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circ Res 85 (1999) 403
16. Saraste A., Pulkki K., Kallajoki M., et al. Apoptosis in human acute myocardial infarction. Circulation 95 (1997) 320
17. Piper H.M., Garcia-Dorado D., and Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 38 (1998) 291-300
18. Lemasters J.J., Bond J.M., Chacon E., et al. The pH paradox in ischemia-reperfusion injury to cardiac myocytes. EXS 76 (1996) 99-114
19. Jonassen A.K., Sack M.N., Mjos O.D., and Yellon D.M. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 89 (2001) 1191-1198
20. Apstein C.S., and Opie L.H. A challenge to the metabolic approach to myocardial ischaemia. Eur Heart J 26 (2005) 956-959
21. Zweier J.L. Measurement of superoxide- derived free radicals in the reperfused heart: evidence for a free radical mechanism of reperfusion injury. J Biol Chem 263 (1988) 1353-1357
22. Hearse D.J., Humphrey S.M., and Chain E.B. Abrupt reoxygenation of the anoxic potassium- arrested perfused rat heart: a study of myocardial enzyme release. J Mol Cell Cardiol 5 (1973) 395-407
23. Klein H.H., Pich S., Lindert S., Nebendahl K., Warneke G., and Kreuzer H. Treatment of reperfusion injury with intracoronary calcium channel antagonists and reduced coronary free calcium concentration in regionally ischemic, reperfused porcine hearts. J Am Coll Cardiol 13 (1989) 1395-1401
24. Carry M.M., Mrak R.E., Murphy M.L., Peng C.F., Straub K.D., and Fody E.P. Reperfusion injury in ischemic myocardium: protective effects of ruthenium red and of nitroprusside. Am J Cardiovasc Pathol 2 (1989) 335-344
25. Gumina R.J., Buerger E., Eickmeier C., Moore J., Daemmgen J., and Gross G.J. Inhibition of the Na(+)/H(+) exchanger confers greater cardioprotection against 90 minutes of myocardial ischemia than ischemic preconditioning in dogs. Circulation 100 (1999) 2519-2526
26. Bond J.M., Herman B., and Lemasters J.J. Protection by acidotic pH against anoxia/reoxygenation injury to rat neonatal cardiac myocytes. Biochem Biophys Res Commun 179 (1991) 798-803
27. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 61 (2004) 481-497
28. Bolli R., Becker L., Gross G., Mentzer Jr. R., Balshaw D., and Lathrop D.A. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 95 (2004) 125-134
29. Halestrap A.P., Clarke S.J., and Javadov S.A. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc Res 61 (2004) 372
30. Javadov S., and Karmazyn M. Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cell Physiol Biochem 20 (2007) 1-22
31. Crompton M., and Costi A. A heart mitochondrial Ca2(+)-dependent pore of possible relevance to re-perfusion-induced injury. Evidence that ADP facilitates pore interconversion between the closed and open states. Biochem J 266 (1990) 33-39
32. Hunter D.R., and Haworth R.A. The Ca-induced membrane transition in mitochondria. Arch Biochem Biophys 195 (1979) 468-477
33. Bernardi P., and Petronilli V. The permeability transition pore as a mitochondrial calcium release channel: a critical appraisal. J Bioenerg Biomembr 28 (1996) 131-138
34. Zhao Z.Q., Corvera J.S., Halkos M.E., et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. (published correction appears I in Am J Physiol Heart Circ Physiol 2004;286:H477). Am J Physiol Heart Circ Physiol 285 (2003) H579-H588
35. Hausenloy D.J., and Yellon D.M. The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol 35 (2003) 339-341
36. Hausenloy D.J., and Yellon D.M. Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 116 (2007) 173-191
37. Hausenloy D.J., and Yellon D.M. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK) pathway. Cardiovasc Res 61 (2004) 448-460
38. Hausenloy D.J., and Yellon D.M. Reperfusion injury salvage kinase signaling: taking a RISK for cardioprotection. Heart Fail Rev 12 (2007) 217-234
39. Hausenloy D.J., Tsang A., and Yellon D.M. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 15 (2005) 69-75
40. Leshnower B.G., Kanemoto S., Matsubara M., et al. Cyclosporine preserves mitochondrial morphology after myocardial ischemia/reperfusion independent of calcineurin inhibition. Ann Thorac Surg 86 (2008) 1286-1292
41. Pagel P.S., and Krolikowski J.G. Transient metabolic alkalosis during early reperfusion abolishes helium preconditioning against myocardial infarction: restoration of cardioprotection by cyclosporin A in rabbits. Anesth Analg 108 (2009) 1076-1082
42. Nathan M., Friehs I., Choi Y.H., et al. Cyclosporin A but not FK-506 protects against dopamine-induced apoptosis in the stunned heart. Ann Thorac Surg 79 (2005) 1620-1626
43. Niemann C.U., Saeed M., Akbari H., et al. Close association between the reduction in myocardial energy metabolism and infarct size: dose-response assessment of cyclosporine. J Pharmacol Exp Ther 302 (2002) 1123-1128
44. Piot C., Croisille P., Staat P., et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359 (2008) 473-481
45. Oie E., Bjørnerheim R., Clausen O.P., and Attramadal H. Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats. Am J Physiol Heart Circ Physiol 278 (2000) 2115-2123
46. Molkentin J.D., Lu J.R., Antos C.L., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93 (1998) 215-228
47. Youn T.J., Piao H., Kwon J.S., et al. Effects of the calcineurin dependent signaling pathway inhibition by cyclosporin A on early and late cardiac remodeling following myocardial infarction. Eur J Heart Fail 4 (2002) 713-718
48. Romero-Perez D., Fricovsky E., Yamasaki K.G., et al. Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. J Am Coll Cardiol 52 (2008) 1086-1094